Session Title: Free Paper Session 9: AMD III
Session Date/Time: Friday 08/09/2017 | 08:00-09:30
Paper Time: 08:12
Venue: Room 117
First Author: : Y.Oshima JAPAN
Co Author(s): : Y. Umeno N. Umeda T. Nagata K. Sonoda T. Ishibashi
To evaluate the correlation between visual acuity improvement and QOL measurement after ranibizumab treatment for Japanese AMD patients.
This study was a one-year prospective, interventional, open-label, multicentre study involving four sites.
Patients with wet AMD were enrolled and observed for a period of 12 months. Patients who were treatment naïve were received 0.5mg ranibizumab as needed (PRN) after three initial monthly dosing. The best corrected visual acuity (BCVA) and central macular thickness measured by OCT were collected every visit, and fluorescein and indocyanine green angiography, the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25), and patient satisfaction questionnaire were performed at baseline, after three months and twelve months of initial treatment. The primary end point was the change of BCVA and QOL three months after ranibizumab treatment.
The study was enrolled 100 patients. The mean log MAR BCVA after three months treatment was improved significantly from 0.43 to 0.30 (p<0.0001). The mean NEI VFQ-25 composite scores were higher after three months of ranibizumab treatment, improving 79.48 to 84.13 (p<0.0001). There was significantly correlation in the NEI VFQ-25 score change and BCVA change in baseline visual acuity worse group (decimal BCVA below 0.5, p=0.02) but not in baseline visual acuity better group (decimal BCVA above 0.6, p=0.1) after the 3 loading treatments. There were no significantly differences in the satisfaction questionnaire score from baseline to after 3 loading treatments (P=0.5466). The average central foveal thickness improved significantly from 340μm to 264 μm after the 3 loading doses (p<0.0001).
Intravitreal ranibizumab treatment for Japanese AMD patients was resulted in improvement of visual acuity, anatomical change, and visual function change. Significant improvement was seen in the patient visual function, but this was not correlated to change in VA in patients with higher, or lower baseline VA.